Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15260105 | 0.93 | MTOR (0.36) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282424 | 0.90 | ABL1 (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17243951 | 0.89 | ABL1 (0.37) | PIK3CDABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10235367 | 0.88 | ABL1 (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283072 | 0.87 | ABL1 (0.35) | ABL1 | |
| SCHEMBL1282207 | 0.87 | ABL1 (0.40) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282907 | 0.87 | ABL1 (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282872 | 0.86 | FGFR3 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282659 | 0.86 | ABL1 (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283328 | 0.86 | ABL1 (0.39) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | PIK3CD 1471/4885P2RY1 3368/4885ABL1 537/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | PIK3CD 442/4885P2RY1 3728/4885ABL1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.